AstraZeneca's Covid-19vaccine trial in the US is expected to resume as early as this week after theUS Food and Drug Administration completed its review of a serious illness,sources told Reuters.AstraZeneca's large,late-stage US trial has been on hold since September 6 after avolunteers in the company's UK trial fell ill with what was suspected to be arare spinal inflammatory disorder called transverse myelitis.
The sources said theywere told the trial could resume this week. It was unclear how the FDA wouldclassify the illness, they said.UK regulatoryofficials previously reviewed the illness and determined there was“insufficient evidence to say for certain” that it was or was not related tothe vaccine. They allowed the trial to resume in the UK.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Velit omnis animi et iure laudantium vitae, praesentium optio, sapiente distinctio illo?